Neural Noise- On August 26, 2026, Paradromics received an FDA approval letter expanding which computing devices may connect to its Connexus brain-computer interface within the Connect-One Early Feasibility Study, the first IDE-approved fully implantable speech-restoration BCI trial.1
- Under the expansion, compatible personal internet-connected devices — laptops, tablets, and phones — can be added to the study without Paradromics seeking per-device FDA approval, a structural change that moves the platform toward real-world personal digital environments.1
- The approval applies to Convey, Paradromics’ user-facing system that translates decoded neural intent into communication and computer control; the underlying clinical care model of Connect-One is unchanged.1
- Paradromics simultaneously announced that a second patient has been identified for the feasibility study, and that its first patient — a Michigan woman with motor neuron disease implanted in June 2026 — has progressed to the closed-loop stage of the trial.1
- The Connexus implant is a metallic disk smaller than a dime carrying 421 microwire electrodes that interface with brain tissue to capture single-neuron signals; the device holds two FDA Breakthrough Device Designations, one for speech restoration and one for computer control.2
- This regulatory flexibility signals a shift in FDA treatment of neural interface software: rather than being confined to hospital-grade hardware environments, BCI software is beginning to be evaluated as capable of operating within everyday personal devices.2